Volume 26, Number 2—February 2020
Dispatch
Surge in Anaplasmosis Cases in Maine, USA, 2013–2017
Table 2
Year | Hospitalizations |
Tick panels† |
||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
HGA |
Lyme, all ages | |||||||||||
All ages | 0–17 y | 18–64 y | >65 y | MML-R | MML-NE | Total MML | NorDx | All | ||||
2013 | 36 | 0 | 9 | 27 | 66 | 0 | 773 | 773 | 0 | 773 | ||
2014 | 75 | 0 | 25 | 50 | 55 | 0 | 1,479 | 1,479 | 0 | 1,479 | ||
2015 | 68 | 0 | 19 | 49 | 45 | 0 | 1,066 | 1,066 | 875 | 1,941 | ||
2016 | 123 | 0 | 42 | 81 | 47 | 596 | 122 | 718 | 5,259 | 5,977 | ||
2017 |
119 |
0 |
24 |
95 |
48 |
973 |
0 |
973 |
8,184 |
9,157 |
||
Change 2013–2017 | +231% | +167% | +252% | −27% | +1,085% |
*Hospitalizations are Maine hospital inpatient encounters, provided through the Maine Health Data Organization. HGA, human granulocytic anaplasmosis; MML, Mayo Medical Laboratories.
†Tick panels performed at Mayo Clinic Rochester, Rochester, MN, USA (MML-R); MML, New England, Andover, MA, USA (MML-NE, closed in 2016); and NorDx, Scarborough, ME, USA.
Page created: January 20, 2020
Page updated: January 20, 2020
Page reviewed: January 20, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.